Efficacy of desloratadine, 5 mg, compared with fexofenadine, 180 mg, in patients with symptomatic seasonal allergic rhinitis

Allergy and Asthma Proceedings

Volumn 27, Issue 3, 2006, Pages 214-223

  Berger, William E ^a   Lumry, William R ^b   Meltzer, Eli O ^c   Pearlman, David S ^d  

^a Allergy & Asthma Associates of Southern California   (United States)

^b Allergy and Asthma Specialists   (United States)

^c ALLERGY AND ASTHMA MEDICAL GROUP AND RESEARCH CENTER   (United States)

^d Respiratory Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DESLORATADINE; DRUG DERIVATIVE; FEXOFENADINE; HISTAMINE H1 RECEPTOR ANTAGONIST; LORATADINE; TERFENADINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HAY FEVER; HUMAN; MALE; MIDDLE AGED; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; UNITED STATES;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; DOUBLE-BLIND METHOD; FEMALE; HISTAMINE H1 ANTAGONISTS, NON-SEDATING; HUMANS; LORATADINE; MALE; MIDDLE AGED; RHINITIS, ALLERGIC, SEASONAL; TERFENADINE; TREATMENT OUTCOME; UNITED STATES;

EID: 33746630970     PISSN: 10885412     EISSN: None     Source Type: Journal    
DOI: 10.2500/aap.2006.27.2851     Document Type: Article

References (36)

1. Bronsky E. The burden of allergic disease. Patient Care Spring (Suppl):1-6, 2002.
2. D'Alonzo GE Jr. Scope and impact of allergic rhinitis. J Am Osteopath Assoc 102:52-56, 2002.
3. Bauchau V, and Durham SR. Prevalence and rate of diagnosis of allergic rhinitis in Europe. Eur Respir J 24:758-764, 2004.
4. Reed SD, Lee TA, and McCrory DC. The economic burden of allergic rhinitis: A critical evaluation of the literature. Pharmacoeconomics 22:345-361, 2004.
5. Baraniuk JN. Pathogenesis of allergic rhinitis. J Allergy Clin Immunol 99:5763-8772, 1997.
6. Bousquet J, van Cauwenberge P, and Khaltaev N, and Aria Workshop Group, World Health Organization. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 108:S147-S334, 2001.
7. Agrawal DK. Anti-inflammatory properties of desloratadine. Clin Exp Allergy 34:1342-1348, 2004.
8. Allocco FT, Votypka V, deTineo M, et al. Effects of fexofenadine on the early response to nasal allergen challenge. Ann Allergy Asthma Immunol 89:578-584, 2002.
9. Horak F, Stübner P, Zieglmayer R, et al. Comparisons of the effects of desloratadine 5-mg and placebo on nasal airflow and seasonal allergic rhinitis symptoms induced by grass pollen exposure. Allergy 58:481-485, 2003.
10. Day JH, Briscoe MP, Welsh A, et al. Onset of action, efficacy, and safety of a single dose of fexofenadine hydrochloride for ragweed allergy using an environmental exposure unit. Ann Allergy Asthma Immunol 79:533-540, 1997.
11. Greisner WA III. Onset of action for the relief of allergic rhinitis symptoms with second-generation antihistamines. Allergy Asthma Proc 25:81-83, 2004.
12. Salmun LM, and Lorber R. 24-hour efficacy of once-daily desloratadine therapy in patients with seasonal allergic rhinitis [ISRCTN32042139], BMC Fam Pract 3:14, 2002.
13. Simons FE, and Simons KJ. Clinical pharmacology of new histamine H1 receptor antagonists. Clin Pharmacokinet 36:329-352, 1999.
14. Brunton SA. Allergy management strategies: An update. Patient Care Spring (Suppl):16-25, 2002.
15. Kreutner W, Hey JA, Anthes J, et al. Preclinical pharmacology of desloratadine, a selective and nonsedating histamine H1 receptor antagonist. 1st communication: Receptor selectivity, antihistaminic activity, and antiallergenic effects. Arzneimittelforschung 50:345-352, 2000.
16. Golightly LK, and Greos LS. Second-generation antihistamines: Actions and efficacy in the management of allergic disorders. Drugs 65:341-384, 2005.
17. Meltzer EO, Prenner BM, and Nayak A, and the Desloratadine Study Group. Efficacy and tolerability of once-daily 5mg desloratadine, an H1-receptor antagonist, in patients with seasonal allergic rhinitis: assessment during the spring and fall allergy seasons. Clin Drug Invest 21:25-32, 2001.
18. Bachert C, Virchow JC, and Plenker A. Desloratadine in the treatment of seasonal allergic rhinitis: Results of a large observational study. Clin Drug Invest 22:43-52, 2002.
19. Casale TB, Andrade C, and Qu R. Safety and efficacy of once-daily fexofenadine HCl in the treatment of autumn seasonal allergic rhinitis. Allergy Asthma Proc 20:193-198, 1999.
20. Nayak AS, and Schenkel E. Desloratadine reduces nasal congestion in patients with intermittent allergic rhinitis. Allergy 56:1077-1080, 2001.
21. Horak F, Stübner UP, Zieglmayer R, et al. Effect of desloratadine versus placebo on nasal airflow and subjective measures of nasal obstruction in subjects with grass pollen-induced allergic rhinitis in an allergen-exposure unit. J Allergy Clin Immunol 109:956-961, 2002.
22. Ciprandi G, Cosentino C, Milanese M, et al. Fexofenadine reduces nasal congestion in perennial allergie rhinitis. Allergy 56:1068-1070, 2001.
23. Affrime M, Banfield C, Gupta S, et al. Effect of race and sex on single and multiple dose pharmacokinetics of desloratadine. Clin Pharmacokinet 41(suppl 1):21-28, 2002.
24. Kaplan AP, Spector SL, Meeves S, et al. Once-daily fexofenadine treatment for chronic idiopathic urticaria: A multicenter, randomized, double-blind, placebo-controlled study. Ann Allergy Asthma Immunol 94:662-669, 2005.
25. Wilson AM, Haggart K, Sims EJ, et al. Effects of fexofenadine and desloratadine on subjective and objective measures of nasal congestion in seasonal allergic rhinitis. Clin Exp Allergy 32: 1504-1509, 2002.
26. Schering-Plough. Claritin (loratadine) prescribing information. Kenilworth, NJ, 2000.
27. Smolensky MH, Reinberg A, and Labrecque G. Twenty-four hour pattern in symptom intensity of viral and allergic rhinitis: Treatment implications. J Allergy Clin Immunol 95:1084-1096, 1995.
28. Bremond-Gignac D. The clinical specturm of ocular allergy. Curr Allergy Asthma Rep 2:321-324, 2002.
29. Venza I, Visalli M, Ceci G, et al. Quantitative determination of histamine in tears during conjunctivitis by a novel HPLC method. Ophthalmic Res 36:62-69, 2004.
30. Peters-Golden M, and Henderson WR. The role of leukotrienes in allergic rhinitis. Ann Allergy Asthma Immunol 94:609-618, 2005.
31. Nathan RA. Pharmacotherapy for allergic rhinitis: A critical review of leukotriene receptor antagonists compared with other treatments. Ann Allergy Asthma Immunol 9:182-191, 2003.
32. Scadding GK. Desloratadine in the treatment of nasal congestion in seasonal allergic rhinitis. Preclinical and clinical evidence. Clin Drug Invest 22:21-32, 2002.
33. Limon L, and Kockler DR. Desloratadine: A nonsedating anti-histamine. Ann Pharmacother 37:237-246, quiz 313-316, 2003.
34. Meltzer EO, Casale TB, Nathan RA, et al. Once-daily fexofenadone HCl improves quality of life and reduces work and activity impairment in patients with seasonal allergic rhinitis. Ann Allergy Asthma Immunol 83:311-317, 1999.
35. Scharf MB, Kay G, Rikken G, et al. Desloratadine has no effect on wakefulness or psychomotor performance. Allergy 55(suppl 63):280, 2000.
36. Wilken JA, Kane RL, Ellis AK, et al. A comparison of the effect of diphenhydramine and desloratadine on vigilance and cognitive function during treatment of ragweed-induced allergic rhinitis. Ann Allergy Asthma Immunol 91:375-385, 2003.